We are pleased share this story that published on May 3: https://patientworthy.com/2023/05/03/dtx-pharma-developing-cmt1a-rna-therapeutics/
One of the early programs CMTRF funded was DTx, a young company that had developed a new platform for RNA therapeutics. DTx was working on a different disease when senior executives from CMTRF approached them and explained how their FALCON tech could be relevant to CMT research. CMTRF provided DTx Pharma with initial funding in January 2019 for a CMT1A project.
The success of that work earned DTx a grant from the NIH and CMTRF helped build a case that enabled DTx to close a series B round of financing with CMT as its lead indication. Additional institutional financing is in the works.
DTx Pharma is currently conducting the required safety studies in animals to support an Investigational New Drug (IND) application to the FDA for a CMT1A treatment. Clinical trials are expected to start in late 2023 or early 2024.